v3.19.3
Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit (Unaudited) - USD ($)
$ in Thousands
Preferred Stock [Member]
Series A Redeemable Convertible Preferred Stock [Member]
Preferred Stock [Member]
Series B Redeemable Convertible Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance (in shares) at Dec. 31, 2016 56,321,165 51,069,262 140,362      
Balance at Dec. 31, 2016 $ 12,734 $ 15,897 $ 20 $ 118 $ (19,733) $ (19,595)
Exercise of warrants (in shares) 351,493          
Exercise of warrants $ 80          
Stock-based compensation expense       301   301
Net loss         (11,561) (11,561)
Balance (in shares) at Dec. 31, 2017 2,034,548 1,833,387 701,808      
Balance at Dec. 31, 2017 $ 12,814 $ 15,897 $ 20 419 (31,294) (30,855)
Stock-based compensation expense 75 75
Net loss (1,523) (1,523)
Balance (in shares) at Mar. 31, 2018 2,034,548 1,833,387 701,808      
Balance at Mar. 31, 2018 $ 12,814 $ 15,897 $ 1 513 (32,817) (32,303)
Balance (in shares) at Dec. 31, 2017 2,034,548 1,833,387 701,808      
Balance at Dec. 31, 2017 $ 12,814 $ 15,897 $ 20 419 (31,294) (30,855)
Net loss           (2,946)
Balance (in shares) at Jun. 30, 2018 2,034,548 1,833,387 701,808      
Balance at Jun. 30, 2018 $ 12,814 $ 15,897 $ 1 588 (34,239) (33,650)
Balance (in shares) at Dec. 31, 2017 2,034,548 1,833,387 701,808      
Balance at Dec. 31, 2017 $ 12,814 $ 15,897 $ 20 419 (31,294) (30,855)
Stock-based compensation expense       309   309
Net loss         (5,985) (5,985)
Balance (in shares) at Dec. 31, 2018 2,034,548 1,833,387 701,808      
Balance at Dec. 31, 2018 $ 12,814 $ 15,897 $ 20 728 (37,279) (36,531)
Balance (in shares) at Mar. 31, 2018 2,034,548 1,833,387 701,808      
Balance at Mar. 31, 2018 $ 12,814 $ 15,897 $ 1 513 (32,817) (32,303)
Stock-based compensation expense 75 75
Net loss (1,422)  
Balance (in shares) at Jun. 30, 2018 2,034,548 1,833,387 701,808      
Balance at Jun. 30, 2018 $ 12,814 $ 15,897 $ 1 588 (34,239) (33,650)
Balance (in shares) at Dec. 31, 2018 2,034,548 1,833,387 701,808      
Balance at Dec. 31, 2018 $ 12,814 $ 15,897 $ 20 728 (37,279) (36,531)
Stock-based compensation expense 84 84
Net loss (2,462) (2,462)
Balance (in shares) at Mar. 31, 2019 2,034,548 1,833,387 701,808      
Balance at Mar. 31, 2019 $ 12,814 $ 15,897 $ 1 831 (39,741) (38,909)
Balance (in shares) at Dec. 31, 2018 2,034,548 1,833,387 701,808      
Balance at Dec. 31, 2018 $ 12,814 $ 15,897 $ 20 728 (37,279) (36,531)
Net loss           (7,138)
Balance (in shares) at Jun. 30, 2019 5,807,877      
Balance at Jun. 30, 2019 $ 6 35,160 (44,417) (9,251)
Balance (in shares) at Mar. 31, 2019 2,034,548 1,833,387 701,808      
Balance at Mar. 31, 2019 $ 12,814 $ 15,897 $ 1 831 (39,741) (38,909)
Stock-based compensation expense 84 84
Net loss (4,676)  
Conversion of convertible notes into convertible preferred stock (in shares) (367,041)      
Conversion of convertible notes into convertible preferred stock $ 3,203
Recognition of beneficial conversion feature upon conversion of convertible notes $ 2,101
Conversion of of convertible preferred stock into common stock (in shares) (2,034,548) (2,200,428) 4,234,976      
Conversion of of convertible preferred stock into common stock $ (12,814) $ (21,201) $ 4 34,011 34,015
Issuance of common stock for merger (in shares) 854,017      
Issuance of common stock for merger $ 1 1 2
Equity issuance costs paid in stock (in shares) 17,076      
Equity issuance costs paid in stock
Impact of change of warrants subject to fair value measure to equity warrants 234 234
Spin-off of AquaMed (1) (1)
Balance (in shares) at Jun. 30, 2019 5,807,877      
Balance at Jun. 30, 2019 $ 6 $ 35,160 $ (44,417) $ (9,251)